Amphastar PharmaceuticalsAMPH +1.78%83 Interest Coverage is 2.08 as of Mar. 2026, which is 86% below its 10-year median of 15.02. GuruFocus rates AMPH with a GF Score™ of 83/100 and a GF Value™ of $48.78 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 685 Drug Manufacturers companies, Amphastar Pharmaceuticals ranks worse than 71.97% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Amphastar Pharmaceuticals's
Operating Income
for the
three
months ended in Mar. 2026 was $13.6 Mil. Amphastar Pharmaceuticals's Interest Expense for the
three
months ended in Mar. 2026 was $-6.6 Mil.
Amphastar Pharmaceuticals's interest coverage for the quarter that ended in Mar. 2026 was 2.08.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Amphastar Pharmaceuticals's Interest Coverage or its related term are showing as below:
AMPH'
s Interest Coverage Range Over the Past 10 Years
Min: 4.53 Med: 15.02 Max: 78.97
Current: 4.53
AMPH's Interest Coverage is ranked worse than 71.97% of 685
companies
in the Drug Manufacturers industry
Industry Median: 12.78
vs AMPH: 4.53
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Amphastar Pharmaceuticals Interest Coverage Related Terms
Amphastar Pharmaceuticals Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
AMPH vs ETON, ESPR, BIOA: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amphastar Pharmaceuticals Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Amphastar Pharmaceuticals's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amphastar Pharmaceuticals (AMPH) has a Interest Coverage of 2.08 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Amphastar Pharmaceuticals and its competitors. This is 86% below median its historical median of 15.02. Over the past decade, Amphastar Pharmaceuticals' Interest Coverage has ranged from 4.53 to 78.97. According to the industry distribution chart, Amphastar Pharmaceuticals ranks #493 out of 685 companies in the Drug Manufacturers industry, placing it in the top 72%.
Is Amphastar Pharmaceuticals' Interest Coverage too high?
Amphastar Pharmaceuticals' current Interest Coverage of 2.08 is 86% below median its 10-year median of 15.02. Over the past 10 years, this metric has ranged from a low of 4.53 to a high of 78.97. The Drug Manufacturers industry median Interest Coverage is 12.78. Amphastar Pharmaceuticals' value of 2.08 is 83.7% below this industry median. Based on the distribution chart, Amphastar Pharmaceuticals ranks #493 out of 685 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Amphastar Pharmaceuticals has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' Interest Coverage compare to ETON and ESPR?
According to the Drug Manufacturers industry distribution chart, Amphastar Pharmaceuticals ranks #493 out of 685 companies for Interest Coverage. This places Amphastar Pharmaceuticals in the lower half of its industry. The industry median Interest Coverage is 12.78. Amphastar Pharmaceuticals' value of 2.08 is 83.7% below this benchmark. Historically, Amphastar Pharmaceuticals' own Interest Coverage has ranged from 4.53 to 78.97 over the past decade. While the company's 10-year median is 15.02 vs. the industry median of 12.78, Amphastar Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.78, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amphastar Pharmaceuticals's current Interest Coverage of 2.08 is 83.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Amphastar Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amphastar Pharmaceuticals's current Interest Coverage is 2.08, which is 86% below median its own 10-year median of 15.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.78, compared to a current price of $21.39 — trading 56.2% below its estimated fair value. The current Interest Coverage is 2.08, which is 86% below median its 10-year median of 15.02 and 83.7% below the Drug Manufacturers industry median of 12.78. Amphastar Pharmaceuticals' overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current Interest Coverage is 2.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued.
The current stock price of $21.39 is trading 56.2% below its estimated GF Value™ of $48.78.
GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for AMPH:
Interest Coverage: 2.08 (86% below median its 10-year median of 15.02)
GF Value™: $48.78 vs. price of $21.39 (56.2% below fair value)
Industry Position: 83.7% below the Drug Manufacturers median (#493 of 685)
No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
83GF Score
Get the complete analysis for AMPH
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMPH has been successfully added to your 
